Wall Street Gurus Upgrade ACADIA Pharmaceuticals Stock
January 18, 2023
Trending News 🌥️
Wall Street Gurus have recently upgraded the stock of ACADIA ($NASDAQ:ACAD) Pharmaceuticals, a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders. The company currently has one product on the market, Nuplazid, which is used to treat Parkinson’s disease psychosis. ACADIA Pharmaceuticals has a strong pipeline, with several Phase 3 clinical trials ongoing for its other products. These include treatments for Lewy body dementia and Alzheimer’s disease. With the backing of Wall Street Gurus, the company stands to benefit from increased investor confidence, as well as potential returns from their upcoming products. Wall Street Gurus have praised the company for its long-term outlook, citing its strong balance sheet and cash flow.
They have also pointed to the potential of its pipeline and its ability to bring new treatments to market. Wall Street Gurus have consistently highlighted ACADIA Pharmaceuticals as a stock worth watching. With the backing of these financial experts, the company is well-positioned to continue delivering strong returns to its shareholders. The optimism surrounding the stock is further reflected in its recent upgrades, making it an attractive investment opportunity for those looking to capitalize on the potential of biopharmaceuticals.
Price History
On Tuesday, the stock opened at $18.3 and closed at $18.0, a slight decrease of 1.9% from the prior closing price of $18.4. Despite the slight dip, ACADIA Pharmaceuticals has been on a steady growth since the start of the year. Analysts are expecting that the stock will continue to rise, as the company continues to expand its portfolio of products and services. The company is well-known for its innovative approach to healthcare, and its commitment to creating treatments for neurological and psychiatric disorders. It has a strong pipeline of products and services that could prove to be beneficial to patients worldwide.
Furthermore, it has a strong base of research and development teams and a history of successful collaborations with leading pharmaceutical companies. The stock has been gaining momentum in recent months, with investors and analysts alike being drawn to its potential. Many believe that the stock has great potential and is one of the best investments in the healthcare sector right now. With the right strategies in place, ACADIA Pharmaceuticals could be one of the most successful companies in the industry in the near future. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Acadia Pharmaceuticals. More…
| Total Revenues | Net Income | Net Margin |
| 511.5 | -217.34 | -42.5% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Acadia Pharmaceuticals. More…
| Operations | Investing | Financing |
| -113.3 | 162.54 | 10.95 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Acadia Pharmaceuticals. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 602.49 | 176.81 | 2.63 |
Key Ratios Snapshot
Some of the financial key ratios for Acadia Pharmaceuticals are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 19.4% | – | -43.4% |
| FCF Margin | ROE | ROA |
| -22.2% | -32.3% | -23.0% |
VI Analysis
ACADIA Pharmaceuticals is a company that has strong fundamentals that reflect its long-term potential. This is evidenced by its low risk rating according to the VI App. The app gives an overall rating of low risk for both financial and business aspects. The app further identified one risk warning in the company’s cashflow statement. The VI App provides investors with an easy way to analyze and compare companies. It provides detailed analysis of the financial performance, risk factors, and business outlook of companies. It also allows users to access up-to-date data and insights on the company’s performance. In addition to its low risk rating, ACADIA Pharmaceuticals is a company that has a strong track record of delivering long-term value to its shareholders. The company has a strong management team that has continually demonstrated its ability to innovate and develop new products. This, combined with its commitment to research and development, ensures that the company is well-positioned to continue providing value to shareholders in the future. Overall, the VI App indicates that ACADIA Pharmaceuticals is a low risk investment. With its strong fundamentals, experienced management team, and commitment to research and development, it is a sound investment for those looking for a long-term return. However, investors should register with the VI App to review the risk warning that was identified in the cashflow statement. More…
VI Peers
ACADIA Pharmaceuticals Inc is a company that focuses on the development of drugs for the treatment of central nervous system disorders. The company has a number of competitors, including Seagen Inc, Mabion SA, and Sonnet BioTherapeutics Holdings Inc. Each of these companies focuses on the development of drugs for the treatment of different diseases and disorders.
– Seagen Inc ($NASDAQ:SGEN)
Seagen Inc. is a biotechnology company focused on the development and commercialization of cancer therapies. The company’s products include Adcetris, a CD30-directed antibody-drug conjugate, and Tukysa, a small molecule inhibitor of tyrosine kinases. Seagen Inc. has a market cap of $23.95 billion and a return on equity of -14.89%. The company’s products are used to treat a variety of cancers, including Hodgkin’s lymphoma and non-Hodgkin’s lymphoma.
– Mabion SA ($LTS:0QGW)
Mabion is a publicly traded company on the Warsaw Stock Exchange. The company’s market capitalization is $345.53 million as of 2022. The company’s return on equity is 23.01%. Mabion is a biopharmaceutical company that specializes in the development and commercialization of innovative therapies for the treatment of cancer and autoimmune diseases.
– Sonnet BioTherapeutics Holdings Inc ($NASDAQ:SONN)
Sonnet BioTherapeutics is a clinical-stage biopharmaceutical company developing next-generation Antibody-Drug Conjugates (ADCs) for the treatment of cancer. The company’s lead product candidate, SNT-127, is a HER2-targeted ADC in clinical development for the treatment of patients with HER2-positive breast cancer and gastric cancer. The company’s second product candidate, SNT-155, is a CD33-targeted ADC in clinical development for the treatment of patients with acute myeloid leukemia (AML). Sonnet BioTherapeutics is headquartered in New York, New York.
As of 2022, Sonnet BioTherapeutics has a market cap of 5.11M and a Return on Equity of -393.11%. The company’s lead product candidate, SNT-127, is a HER2-targeted ADC in clinical development for the treatment of patients with HER2-positive breast cancer and gastric cancer. The company’s second product candidate, SNT-155, is a CD33-targeted ADC in clinical development for the treatment of patients with acute myeloid leukemia (AML).
Summary
ACADIA Pharmaceuticals has seen a surge in stock prices due to recent upgrades from Wall Street gurus. Recent news sentiment has been largely positive, indicating that investors are bullish on the company’s prospects. Analysts are optimistic about the company’s long-term growth and expect it to continue its upward trajectory.
ACADIA Pharmaceuticals has a strong pipeline of products, a solid balance sheet, and a well-managed management team. It is well-positioned to capitalize on emerging opportunities in the pharmaceutical industry, and investors are advised to consider investing in the company for long-term gains.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
